Acceptance Limits for the New ICH USP 29 Content-Uniformity Test - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

 Pharmaceutical Technology All results
Acceptance Limits for the New ICH USP 29 Content-Uniformity Test
Revisions to the United States Pharmacopeia's (USP) uniformity test require manufacturers to establish new acceptance limits. The authors present their method for calculating acceptance limits consistent with USP's revised content-uniformity test requirements.
 Oct 2, 2007 Pharmaceutical Technology

Where k = 2.4 for n = 10; k = 2.0 for n = 30; s is the standard deviation of the observations.

Unless otherwise specified, all the measurements of dosage units and criteria values (such as L 1) are in percentage label claim.

Lower probability bound of passing USP

Notice that P(passing USP test)

Assume that the X i 's follow a normal distribution denoted N (μ, σ). Then the values of P(S 1) and P(S 2) can be calculated as described in the following two subsections.

Computation of P(S 1)

Given the definition of AV, it can be seen that:

For T ≤ 101.5

The density function of Z 2 is a x2 distribution with n – 1 degrees of freedom and is denoted as x2 (n – 1).

The joint density function is f(z 1,Z 2) = f 1(z 1) f 2(Z 2),

Given the independence of z 1 and Z 2, P(S 1) can be rewritten in terms of z 1 and Z 2 as:

Computation of P(S 2)

There are two subcriteria in S 2, which are denoted as C 21 and C 22, respectively, as follows:

C 21 = AV of the 30 dosage units is less than or equal to L 1.

C 22 = no unit deviates from the calculated value of M by more than 25% of M.

| Weekly
| Monthly
|Monthly
| Weekly
 Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products 21%
To all process for new products only 13%
To select process for new products only 26%
To select processes for both new and legacy products 21%
Do not use QbD 18%
Most Viewed Articles
 UPCOMING CONFERENCES Programs for Investigational and Pre-Launch Drugs Philadelphia, PA July 17-18, 2013 Request Brochure Strategic Pipeline Planning & Portfolio Valuation Philadelphia, PA August 13-14, 2013 Request Brochure MES 2013 - Forum on Manufacturing Execution Systems Philadelphia, PA August 14-15, 2013 Request Brochure Mobile Innovation for the Life Sciences Industry Philadelphia, PA August 20-21, 2013 Request Brochure See All Conferences >>
 Columnists sponsored by Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy sponsored by Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry sponsored by Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality